#1 Clinical Trials Search in Europe

Octreotide Acetate

Octreotide Acetate, a synthetic analog of somatostatin, is being studied in various clinical trials for its potential benefits in treating different medical conditions. These trials aim to evaluate its efficacy, safety, and tolerability in patients with acromegaly, neuroendocrine tumors, liver cancer, and other conditions. The research focuses on different formulations and administration methods of Octreotide Acetate, including long-acting release (LAR) versions and implants, to improve patient outcomes and quality of life.

Table of Contents

What is Octreotide Acetate?

Octreotide Acetate is a medication that belongs to a class of drugs called somatostatin analogs. It is also known by other names such as Sandostatin, SMS995, and Siroctid [1][2][3]. This medication is designed to mimic the effects of somatostatin, a natural hormone in your body that regulates various functions, particularly in the digestive system and certain glands.

Conditions Treated with Octreotide Acetate

Octreotide Acetate is used to treat several medical conditions, including:

  • Acromegaly: A hormonal disorder that results from the production of too much growth hormone, leading to abnormal growth of body tissues [1][4]
  • Neuroendocrine Tumors (NETs): Rare tumors that can occur in various parts of the body, particularly in the digestive system or lungs [5]
  • Carcinoid Syndrome: A group of symptoms associated with certain types of NETs [6]
  • Pancreatic Fistula: A complication that can occur after pancreatic surgery [3]
  • Diarrhea associated with certain medications: For example, diarrhea caused by mycophenolate mofetil, an immunosuppressant drug [7]

How Octreotide Acetate Works

Octreotide Acetate works by mimicking the action of somatostatin in the body. It helps to:

  • Reduce the production of certain hormones, such as growth hormone and insulin-like growth factor 1 (IGF-1) in acromegaly patients [1]
  • Slow down the growth of tumors in patients with neuroendocrine tumors [5]
  • Control symptoms associated with carcinoid syndrome, such as flushing and diarrhea [6]
  • Reduce pancreatic secretions, which can help in preventing or treating pancreatic fistulas [3]

How Octreotide Acetate is Administered

Octreotide Acetate can be administered in several ways:

  • Short-acting injections: Given subcutaneously (under the skin) multiple times a day [5]
  • Long-acting release (LAR) formulations: Given as intramuscular injections every 28 days [8]
  • Implants: Subcutaneous implants that release the medication over an extended period [4]
  • Experimental formulations: Such as Debio 4126, a 12-week prolonged-release formulation being studied in clinical trials [6]

Ongoing Research and Clinical Trials

Researchers are continuously studying Octreotide Acetate to understand its effects better and explore new potential uses. Some areas of ongoing research include:

  • Its impact on the immune system in patients with neuroendocrine tumors [5]
  • Long-term safety and efficacy in treating acromegaly [8]
  • Comparison with other medications like somatostatin in preventing pancreatic fistulas after surgery [3]
  • Its potential use in treating polycystic kidney disease [9]
  • Its effectiveness in treating advanced liver cancer [10]

Potential Side Effects and Safety Considerations

Like all medications, Octreotide Acetate can cause side effects. Common side effects may include:

  • Gastrointestinal symptoms such as diarrhea, nausea, or abdominal pain
  • Injection site reactions
  • Changes in blood sugar levels
  • Gallbladder problems

It’s important to note that the safety and tolerability of Octreotide Acetate are continually being evaluated in clinical trials [6]. Your healthcare provider will monitor you closely while you’re on this medication and adjust the dosage as needed to minimize side effects while maximizing benefits.

Aspect Details
Drug Name Octreotide Acetate
Conditions Studied Acromegaly, Neuroendocrine Tumors, Liver Cancer, Diarrhea, Liver Transplantation Complications
Administration Methods Subcutaneous, Intramuscular, Intravenous, Implants
Formulations Short-acting, Long-acting Release (LAR), Implants
Primary Outcomes Hormone level reduction, Symptom control, Tumor response, Renal function improvement
Secondary Outcomes Safety profile, Quality of life, Progression-free survival, Blood loss reduction
Potential Benefits Hormone regulation, Tumor growth control, Symptom management, Improved surgical outcomes
Safety Monitoring Adverse events, Blood sugar levels, Heart rhythm, Injection site reactions

FAQ

  • What is Octreotide Acetate? Octreotide Acetate is a synthetic version of somatostatin, a naturally occurring hormone in the body. It is used to treat various medical conditions by helping to regulate certain hormones and bodily functions.
  • What conditions are being studied with Octreotide Acetate in clinical trials? Clinical trials are exploring the use of Octreotide Acetate in conditions such as acromegaly, neuroendocrine tumors, liver cancer, diarrhea associated with certain medications, and complications related to liver transplantation.
  • How is Octreotide Acetate administered in these trials? Octreotide Acetate is administered in various ways depending on the trial, including subcutaneous injections, intramuscular injections, intravenous infusions, and even as implants. Some trials are studying long-acting release (LAR) formulations for less frequent dosing.
  • What are some potential benefits of Octreotide Acetate being studied? Researchers are investigating potential benefits such as reducing hormone levels in acromegaly, controlling symptoms in neuroendocrine tumors, improving outcomes in liver cancer, managing diarrhea, and potentially improving renal function and reducing bleeding during liver transplantation.
  • Are there any side effects associated with Octreotide Acetate? While side effects can vary, some trials are monitoring for potential adverse events such as changes in blood sugar levels, heart rhythm abnormalities, and injection site reactions. The safety and tolerability of Octreotide Acetate are important aspects being studied in these clinical trials.

Ongoing Clinical Trials on Octreotide Acetate

  • Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Hungary Italy The Netherlands Poland +1

  • Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Finland Italy The Netherlands Norway +1

  • Study of Lutetium (177Lu) Oxodotreotide for Patients with Recurrent Meningioma Without Surgery or Radiotherapy Options

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Denmark France Germany Italy The Netherlands +2

  • Study of ALXN2420 with somatostatin analogs for adults with acromegaly to evaluate effectiveness in lowering IGF-1 levels

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Hungary Italy Lithuania The Netherlands Poland +1

  • Study on the Safety and Effects of Paltusotine and Octreotide Acetate for Patients with Carcinoid Syndrome

    Not recruiting

    1 1 1
    Investigated drugs:
    Poland

Glossary

  • Acromegaly: A hormonal disorder that results from too much growth hormone (GH) in the body, usually caused by a benign tumor of the pituitary gland.
  • Neuroendocrine Tumors (NETs): Rare tumors that arise from cells of the endocrine (hormonal) and nervous systems, often found in the digestive tract, lungs, or pancreas.
  • Somatostatin: A hormone that regulates the endocrine system and affects neurotransmission and cell proliferation.
  • Growth Hormone (GH): A hormone produced by the pituitary gland that stimulates growth and cell reproduction in humans and other animals.
  • Insulin-like Growth Factor 1 (IGF-1): A hormone similar in molecular structure to insulin, playing an important role in childhood growth and continuing to have anabolic effects in adults.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and excreted by the body over time.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and relationship between drug concentration and effect.
  • Long-acting Release (LAR): A formulation of a drug designed to release the active ingredient over an extended period, allowing for less frequent dosing.
  • Microadenoma: A small benign tumor, typically less than 10 mm in size, often found in endocrine glands like the pituitary.
  • Macroadenoma: A benign tumor larger than 10 mm in size, often found in endocrine glands like the pituitary.

References

  1. https://clinicaltrials.gov/study/NCT00242541
  2. https://clinicaltrials.gov/study/NCT01086982
  3. https://clinicaltrials.gov/study/NCT03000946
  4. https://clinicaltrials.gov/study/NCT00913055
  5. https://clinicaltrials.gov/study/NCT04129255
  6. https://clinicaltrials.gov/study/NCT05364944
  7. https://clinicaltrials.gov/study/NCT02977897
  8. https://clinicaltrials.gov/study/NCT01295060
  9. https://clinicaltrials.gov/study/NCT01377246
  10. https://clinicaltrials.gov/study/NCT00257426